A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Inclusion Criteria:
Exclusion Criteria:
Philadelphia, Pennsylvania 19104, United States
CABA, C1122, Argentina
Córdoba, 5000, Argentina
Porto Alegre, 90610-000, Brazil
Wuhan, 430022, China
Toyonaka-shi, 560-8552, Japan
Warsaw, 02-781, Poland
Gyeongsangnam-do, 52727, South Korea
Jeollanam-do, 58128, South Korea